Clinical Trials
Advancing the field through innovative therapeutic approaches
The Blood and Marrow Transplantation & Cellular Therapy Division is committed to advancing the field through a robust portfolio of clinical trials that explore innovative therapeutic approaches, including novel cellular immunotherapies and CAR T-cell therapies. As a proud member of the Blood and Marrow Transplant Clinical Trials Network of the National Cancer Institute, our clinical investigators play a pivotal role in designing and implementing studies ranging from early-phase trials to pivotal late-phase research.
These studies aim to evaluate treatment efficacy, understand immune responses, and ensure the smooth translation of research findings into the most advanced patient care available today. Our clinical trials at the Stanford Cancer Center focus on new treatments and complementary therapies, ultimately driving the development of more effective treatment strategies for hematologic diseases and related disorders.
BMT-CT Clinical Trials Recruiting: PI - Surbhi Sidana, MD
Showing 1 - 5 of 5 trials
-
Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma
Stanford is currently accepting patients for this trial. -
Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release
Stanford is currently accepting patients for this trial. -
Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma
Stanford is currently accepting patients for this trial. -
A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies
Stanford is currently accepting patients for this trial. -
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Stanford is currently accepting patients for this trial.